Clinical Trials
20 trialsNCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT06580938 2026-03-23
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Phase 1 Terminated
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT06336148 2025-10-15
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1 Terminated
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT05819827 2025-04-27
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Mayo Clinic
Terminated
NCT04254107 2025-02-10
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Phase 1 Terminated
NCT02554812 2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2 Terminated
NCT03621982 2024-06-13
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT05061537 2024-04-12
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03637803 2023-06-01
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
Phase 1/2 Terminated
NCT04311710 2023-02-24
CheckMate 76U
Bristol-Myers Squibb
Phase 1 Terminated
NCT02628535 2022-02-08
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Phase 1 Terminated
NCT02346955 2020-08-27
MK-6018-001
KitovPharma
Phase 1 Terminated
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02900248 2019-04-02
N1
CureOne
Terminated
NCT00904514 2018-10-05
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Terminated
NCT02543645 2018-04-30
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Phase 1 Terminated
NCT01010334 2013-08-14
Comparison of Standard of Care or Treatment on Protocol
New Mexico Cancer Research Alliance
Phase NA Terminated